Study Summary
This trial is testing a new cancer drug to see if it is safe and effective.
- Advanced Solid Tumors
- Glioblastoma
- Metastatic Melanoma
- Prostate Cancer
- Cancer Brain Metastases
- Metastatic Breast Cancer
- Glioblastoma (GBM)
- Glioblastoma Multiforme
- Breast Cancer
- Hormone-Refractory Prostate Cancer
- Recurrent Melanoma
Treatment Effectiveness
Effectiveness Progress
Study Objectives
2 Primary · 7 Secondary · Reporting Duration: 30 Months
Trial Safety
Safety Progress
Trial Design
7 Treatment Groups
Dose Expansion HR+ Breast
1 of 7
Dose Expansion CRPC
1 of 7
Dose Expansion Recurrent Glioblastoma
1 of 7
Newly Diagnosed Glioblastoma
1 of 7
Dose Expansion Melanoma
1 of 7
Dose Expansion GBM
1 of 7
Dose Escalation
1 of 7
Experimental Treatment
162 Total Participants · 7 Treatment Groups
Primary Treatment: ST101 · No Placebo Group · Phase 1 & 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 8 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
How many participants have joined this research endeavor?
"This clinical trial requires 162 participants who possess the specified inclusion criteria. Those interested in joining this medical research can visit Texas Oncology - Baylor Charles A. Sammons Cancer Center in Dallas, Texas and Northwestern Medicine Cancer Centers in Warrenville, Illinois for enrollment." - Anonymous Online Contributor
Does this experiment bring anything new to the scientific community?
"Since 2020, ST101 has been under investigative scrutiny. Sapience Therapeutics sponsored the first study of 162 participants and then followed it up with successful Phase 1 & 2 drug approvals. Currently, there is one active trial for this product ran by Sapience Therapeutics." - Anonymous Online Contributor
Has ST101 been subject to any other scientific investigations?
"The first instance of research on ST101 was conducted in 2020 by the University of Leeds. To date, there are 3 concluded studies and 1 still ongoing clinical trial based mostly out of Dallas, Texas." - Anonymous Online Contributor
What are the projected outcomes of this investigation?
"This 20-month trial's primary objective is to measure Dose-Limiting Toxicity (DLT). Secondary objectives encompass Area Under the Curve (AUC), Duration of Response, and Cmax." - Anonymous Online Contributor
Are there still vacancies available in this research venture?
"Affirmative. The clinical trial is accepting volunteers as per the data available on clinicaltrials.gov. It was originally listed in July of 2020, with updates made up until November 15th 2022; 162 individuals will be recruited from 8 different medical institutions." - Anonymous Online Contributor
How many healthcare facilities are administering this clinical trial?
"Texas Oncology - Baylor Charles A. Sammons Cancer Center in Dallas, Texas, Northwestern Medicine Cancer Centers in Warrenville, Illinois and Columbia University in New York City are amongst the 8 additional medical centres involved with this test." - Anonymous Online Contributor